Quizartinib
Sign in to save this workspacePrimary targets: FLT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.737
CATDS
0.038
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Quizartinib. Strongest target: FLT3 at 97.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FLT3 | 97.9% | 2.1% |
| 2 | C_KIT | 97.3% | 2.7% |
| 3 | PDGFRB | 89.0% | 11.0% |
| 4 | FMS | 83.7% | 16.3% |
| 5 | RET | 79.5% | 20.5% |
| 6 | MUSK | 79.2% | 20.8% |
| 7 | PDGFRA | 69.8% | 30.3% |
| 8 | TRKB | 57.6% | 42.4% |
| 9 | TRKC | 53.9% | 46.1% |
| 10 | HIPK4 | 53.1% | 46.9% |
| 11 | RIPK4 | 51.4% | 48.6% |
| 12 | DDR1 | 48.2% | 51.8% |
| 13 | ERK7_MAPK15 | 44.3% | 55.7% |
| 14 | KHS_MAP4K5 | 41.4% | 58.6% |
| 15 | TRKA | 39.4% | 60.6% |
| 16 | DDR2 | 38.5% | 61.5% |
| 17 | FLT4_VEGFR3 | 36.3% | 63.7% |
| 18 | CAMKK1 | 34.7% | 65.3% |
| 19 | HGK_MAP4K4 | 33.3% | 66.7% |
| 20 | MYLK3 | 24.5% | 75.5% |
Selectivity landscape
Where Quizartinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Quizartinib.
Annotations
Sign in to read and post annotations.
Loading…